Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
International Journal of Colorectal Disease|August 5, 2009
Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin valuesLaura Mäkitalo, Taina Sipponen, Päivi Kärkkäinen, et al.
Scandinavian Journal of Gastroenterology|September 2, 2011
Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel diseaseTaina Sipponen, Ulla Turunen, Irmeli Lautenschlager, et al.
Scandinavian Journal of Gastroenterology|August 26, 2017
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patientsAnja Eberl, Saara Huoponen, Tapio Pahikkala, et al.
Microbiology Spectrum|July 7, 2025
The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximabRebecka Ventin-Holmberg, Julia Eriksson, Anja Eberl, et al.
Inflammatory Bowel Diseases|November 21, 2007
Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findingsTaina Sipponen, Erkki Savilahti, Kaija-Leena Kolho, et al.
Scandinavian Journal of Gastroenterology|March 13, 2013
Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's diseaseClas-Göran af Björkesten, Urpo Nieminen, Taina Sipponen, et al.
Scandinavian Journal of Gastroenterology|November 4, 2016
Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agentsPauliina Molander, Martti Färkkilä, Helena Kemppainen, et al.
Scandinavian Journal of Gastroenterology|February 24, 2012
Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's diseaseClas-Göran af Björkesten, Urpo Nieminen, Ulla Turunen, et al.
Scandinavian Journal of Gastroenterology|June 22, 2021
Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world settingSara Kolehmainen, Tero Ylisaukko-Oja, Jari Jokelainen, et al.
Inflammatory Bowel Diseases|May 20, 2008
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's diseaseTaina Sipponen, Erkki Savilahti, Päivi Kärkkäinen, et al.
Pageof 7